These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28655984)

  • 1. Bacterial load and cytokine profile in patients with cirrhosis following therapy with proton pump inhibitors: a prospective cohort study.
    Triantos C; Kalafateli M; Spantidea PI; Goukos D; Koutroumpakis E; Konstantakis C; Assimakopoulos SF; Gogos C; Mouzaki A; Daikos G; Thomopoulos K
    Ann Gastroenterol; 2017; 30(4):450-456. PubMed ID: 28655984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.
    Papp M; Sipeki N; Vitalis Z; Tornai T; Altorjay I; Tornai I; Udvardy M; Fechner K; Jacobsen S; Teegen B; Sumegi A; Veres G; Lakatos PL; Kappelmayer J; Antal-Szalmas P
    J Hepatol; 2013 Sep; 59(3):457-66. PubMed ID: 23639483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
    de Vos M; De Vroey B; Garcia BG; Roy C; Kidd F; Henrion J; Deltenre P
    Liver Int; 2013 Oct; 33(9):1316-23. PubMed ID: 23730823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.
    Okura Y; Namisaki T; Sato S; Moriya K; Akahane T; Kitade M; Kawaratani H; Kaji K; Takaya H; Sawada Y; Shimozato N; Seki K; Saikawa S; Nakanishi K; Furukawa M; Fujinaga Y; Kubo T; Kaya D; Tsuji Y; Ozutsumi T; Kitagawa K; Mashitani T; Ogawa H; Ishida K; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2019 Feb; 49(2):232-238. PubMed ID: 30198141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis.
    Garcia-Martinez I; Francés R; Zapater P; Giménez P; Gómez-Hurtado I; Moratalla A; Lozano-Ruiz B; Bellot P; González-Navajas JM; Such J
    J Gastroenterol Hepatol; 2015 Jan; 30(1):147-54. PubMed ID: 25039465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability.
    van Vlerken LG; Huisman EJ; van Hoek B; Renooij W; de Rooij FW; Siersema PD; van Erpecum KJ
    Eur J Clin Invest; 2012 Jul; 42(7):760-7. PubMed ID: 22288900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
    Dam G; Vilstrup H; Watson H; Jepsen P
    Hepatology; 2016 Oct; 64(4):1265-72. PubMed ID: 27474889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites.
    Dam G; Vilstrup H; Andersen PK; Bossen L; Watson H; Jepsen P
    Liver Int; 2019 Mar; 39(3):514-521. PubMed ID: 30472808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.
    Bajaj JS; Zadvornova Y; Heuman DM; Hafeezullah M; Hoffmann RG; Sanyal AJ; Saeian K
    Am J Gastroenterol; 2009 May; 104(5):1130-4. PubMed ID: 19337238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites.
    Siple JF; Morey JM; Gutman TE; Weinberg KL; Collins PD
    Ann Pharmacother; 2012 Oct; 46(10):1413-8. PubMed ID: 23032651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis.
    Merli M; Lucidi C; Di Gregorio V; Giannelli V; Giusto M; Ceccarelli G; Riggio O; Venditti M
    Liver Int; 2015 Feb; 35(2):362-9. PubMed ID: 24836902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study.
    Terg R; Casciato P; Garbe C; Cartier M; Stieben T; Mendizabal M; Niveyro C; Benavides J; Marino M; Colombato L; Berbara D; Silva M; Salgado P; Barreyro F; Fassio E; Gadano A;
    J Hepatol; 2015 May; 62(5):1056-60. PubMed ID: 25481567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
    Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between proton pump inhibitor use and spontaneous bacterial peritonitis.
    Campbell MS; Obstein K; Reddy KR; Yang YX
    Dig Dis Sci; 2008 Feb; 53(2):394-8. PubMed ID: 17616817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis.
    Kim JH; Lim KS; Min YW; Lee H; Min BH; Rhee PL; Kim JJ; Koh KC; Paik SW
    J Gastroenterol Hepatol; 2017 May; 32(5):1064-1070. PubMed ID: 28449345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of TNF-receptors in peripheral blood mononuclear cells of patients with alcoholic cirrhosis.
    Hanck C; Glatzel M; Singer MV; Rossol S
    J Hepatol; 2000 Jan; 32(1):51-7. PubMed ID: 10673067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.
    Ardevol A; Ibañez-Sanz G; Profitos J; Aracil C; Castellvi JM; Alvarado E; Cachero A; Horta D; Miñana J; Gomez-Pastrana B; Pavel O; Dueñas E; Casas M; Planella M; Castellote J; Villanueva C
    Hepatology; 2018 Apr; 67(4):1458-1471. PubMed ID: 28714072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study.
    Min YW; Lim KS; Min BH; Gwak GY; Paik YH; Choi MS; Lee JH; Kim JJ; Koh KC; Paik SW; Yoo BC; Rhee PL
    Aliment Pharmacol Ther; 2014 Sep; 40(6):695-704. PubMed ID: 25078671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does long-term use of proton pump inhibitors cause hypomagnesaemia in Japanese outpatients?
    Takeda Y; Doyama H; Tsuji K; Yamada S; Takemura K
    BMJ Open Gastroenterol; 2014; 1(1):e000003. PubMed ID: 26462261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study.
    Vogt A; Reuken PA; Stengel S; Stallmach A; Bruns T
    World J Gastroenterol; 2016 Mar; 22(11):3275-84. PubMed ID: 27004006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.